Figures computed from official regulatory filings — .
Analysttarget 278.86 USD (+6%) · consensus 4.3/5 · 24 buy · 5 hold · 1 sell
Ownershipinsiders 0.11% · institutions 77.34% · short 1.2% of float
In USD · as of Oct 5, 2026
Ask the machine
Search and compare insider transactions, companies and their statistics in plain language. Your question becomes a query over available data, not a conversation or investment advice.
Data for AbbVie Inc. only. No web search. Global per-insider statistics are excluded.
An executed search uses one credit, even with no results. Errors and unsupported questions use no credits.
AbbVie Inc., a research-based biopharmaceutical company, engages in the research and development, manufacturing, commercializing, and sale of medicines and therapies worldwide. The company offers Skyrizi to treat autoimmune diseases; Rinvoq to treat inflammatory diseases; Imbruvica for the treatment of adult patients with blood cancers; Venclexta to treat blood cancers; Elahere to treat various cancer; and Epkinly to treat lymphoma; and Emrelis for the treatment of lung cancer. It also provides facial injectables, plastics and regenerative medicine, body contouring, and skincare products; botox Cosmetic for the treatment of glabellar lines, crow's feet, forehead lines, and platysma bands; Juvederm Collection to treat volume loss in the temples, undereye, cheeks, chin, lips and lower face; Vraylar to treat schizophrenia, bipolar disorder, and depressive disorder; Duodopa to treat Parkinson's disease; Ubrelvy to treat migraine; Qulipta for episodic and chronic migraine; and Vyalev for the treatment of motor fluctuations, as well as Botox Therapeutic to treat chronic migraine, overactive bladder, spasticity, cervical dystonia, and other conditions. In addition, the company offers Ozurdex for visual impairment; Lumigan/Ganfort and Alphagan/Combigan for the reduction of elevated intraocular pressure in patients with open angle glaucoma or ocular hypertension; and other eye care products, including Refresh/Optive, Xen, Durysta, and Restasis. Further, it provides Mavyret to treat chronic hepatitis C virus genotype 1-6 infection; Creon, a pancreatic enzyme therapy; and Linzess/Constella to treat irritable bowel syndrome with constipation and chronic idiopathic constipation. The company was incorporated in 2012 and is headquartered in North Chicago, Illinois.
Market information source · Oct 5, 2026
SEC company identity · Oct 5, 2026
Open-market timeline · full history
27 buys540 sells— close pricebar = usd volume, √ scaleclick a period to filter the table
| Insider | Type | Value · USD | Signals | Details |
|---|---|---|---|---|
| Quaggin Susan E | AwardD (derivative) | $15.4K | SEC |
| RAPP EDWARD Jtrack record | AwardD (derivative) | $33.7K | SEC |
| Donoghoe Nicholas | ExerciseD (derivative) | n/a (Non-cash transaction: the filing states a price of zero (award, gift, exercise)) | SEC |
| Donoghoe Nicholas | Sell | $8.2M | Unusual size | SEC |
| Donoghoe Nicholas | Exercise | $2.6M | SEC |
| Quaggin Susan E | AwardD (derivative) | $15.6K | SEC |
| RAPP EDWARD Jtrack record | AwardD (derivative) | $33.7K | SEC |
| FALK THOMAS J | Award | n/a (Non-cash transaction: the filing states a price of zero (award, gift, exercise)) | SEC |
| Quaggin Susan E | Award | n/a (Non-cash transaction: the filing states a price of zero (award, gift, exercise)) | Unusual size | SEC |
| Davis Jennifer L. | Award | n/a (Non-cash transaction: the filing states a price of zero (award, gift, exercise)) | SEC |
| BURNSIDE WILLIAM H.L. | Award | n/a (Non-cash transaction: the filing states a price of zero (award, gift, exercise)) | SEC |
| RAPP EDWARD Jtrack record | Award | n/a (Non-cash transaction: the filing states a price of zero (award, gift, exercise)) | SEC |
| Hart Brett J | Award | n/a (Non-cash transaction: the filing states a price of zero (award, gift, exercise)) | SEC |
| MEYER MELODY B | Award | n/a (Non-cash transaction: the filing states a price of zero (award, gift, exercise)) | SEC |
| FREYMAN THOMAS C | Award | n/a (Non-cash transaction: the filing states a price of zero (award, gift, exercise)) | SEC |
| AUSTIN ROXANNE Strack record | Award | n/a (Non-cash transaction: the filing states a price of zero (award, gift, exercise)) | SEC |
| WADDELL FREDERICK Htrack record | Award | n/a (Non-cash transaction: the filing states a price of zero (award, gift, exercise)) | SEC |
| Roberts Rebecca Btrack record | Award | n/a (Non-cash transaction: the filing states a price of zero (award, gift, exercise)) | SEC |
| Quaggin Susan E | AwardD (derivative) | $15.4K | SEC |
| RAPP EDWARD Jtrack record | AwardD (derivative) | $33.7K | SEC |
| Alpern Robert J | AwardD (derivative) | $7.6K | SEC |
| Purdue David Ryan | Other | $489.2K | SEC |
| Purdue David Ryan | Sell | $1.2M | SEC |
| Crum Demetris D | Other | $369.9K | SEC |
| Reents Scott T | Other | $5M | Unusual size | SEC |